Asset Details
Do you wish to reserve the book?
The Expanding Role of Bevacizumab in the Treatment of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Expanding Role of Bevacizumab in the Treatment of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Do you wish to request the book?
The Expanding Role of Bevacizumab in the Treatment of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Expanding Role of Bevacizumab in the Treatment of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
2010
Overview
A growing body of evidence consistently demonstrates the activity of bevacizumab, a monoclonal antibody that targets all isoforms of vascular endothelial growth factor (VEGF)-A, in combination with chemotherapy in the treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative, metastatic breast cancer. Clinical benefit has been limited to prolonged progression-free survival. As yet, combination regimens have failed to demonstrate a survival advantage. Emerging research suggests that single-nucleotide polymorphism in VEGF may predict response to combined therapy.
Publisher
Current Science Inc
